Table 3. The articles which provided the information about the relationship between the elevated SCCa and the risk of pelvic nodal metastasis.
| Study | Year | Number | SCCa (ng/ml) | Risk Ratio | FIGO Stage | Site of lymph node metastasis |
|---|---|---|---|---|---|---|
| Takeda | 2002 | 103 | >1.5 | 3.7(1.3–10.7) | IB | Pelvic lymph node |
| Zhao | 2016 | 237 | >2.2 | 2.45(1.15–5.24) | IB1-2B | Pelvic lymph node |
| Strauss | 2002 | 129 | >3 | 14 | I -IIB | Pelvic lymph node |
| Huang | 2010 | 960 | >4 | 2.3(1.1–4.8) | IB -IIB | Common iliac lymph node |
| Huang(i) | 2012 | 188 | 10–40 | 4.2(1.7–10.6) | I-IV | PALN metastasis |
| Huang(ii) | 2012 | 188 | >40.0 | 12.6(4.8–32.7) | I-IV | PALN metastasis |
| Ogino | 2005 | 99 | >10.8 | 6.1(2.0–18.5) | IIB-IVA | PALN metastasis |
| Feng | 2005 | 205 | >4.0 | 4.2 | I-IIB | Pelvic lymph node |
| Takeshima | 1998 | 136 | >4.0 | 40.0 | IB | Pelvic lymph node |